N
Google TrendLAMINE YAMAL (2000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Teclistamab in Relapsed o" (30 stories)

Top Headline Story

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Lead StoryNEJMgeneral
May 29

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE16cGJOdl8yWGloUFNwODliZTNhVldhM2xmV1o0ZmJUX2VKUnFfSC1KRFFKd1ZuMWwyU0RVdGhvOEFKWk04X0xlSV9fQTUycXhpTGp0ZS01LTF5Y2xGQ2NhRQ?oc=5" target="_blank">Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+16m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+26m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories
500+26m ago

pope francis

The Myth of St. Francis

Filter stories
500+26m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "Teclistamab in Relapsed o"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Naturegeneral

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNZk1nWEpWUGlOTnNjbVN4T0V0VjdLZmJaVF9nRm1fUzlZbEplM2dVOU5mVU13SEZkYXFOUTB4SWRNTlFuN2M4VEs1WndRVDVHa19fOW9URUxRekNrWkhZ?oc=5" target="_blank">Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
Cureusgeneral

New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight

<a href="https://news.google.com/rss/articles/CBMi1AJBVV95cUxNdmVzR1EwVGtCczRlaXBIc3ltVnhHX3ZsNUhlR0Rra084aXZGS2kwaTNrWlEzMHhTVXJZYVpmR2NGR1JWZjJtVE94YWJ6SV9TUV9faDMxNk9BbHhIcjFEbUkycVFDdHlHOG5XQm4wdE5sb2pEbllqUkVKaUQ3OUR3TnBmUEc5WkNNY2Fid0t2SlBQbS14ZXB6QkthSEZHZG5qS0dmREZ5Sy1YT3ROMnA3d29adkpGX2pHNkZxd2VWdUNubElHWVF1VlZsTlcxYXVXRjFjZFJlVGxiS1RGLS1URDBnbVF5VjB2YkFTZEltM3pXSEoteDY3RzVuM1VJaXpQWnNBaDBVVG5ibnZMY2NNOTJiajh5MHZVMXRUS3c1QWEyX1BVSWYyckg0M1RpTEFMZHhJbnJvZWtxbU1BaW41SGVaeFlUeXJtNVZUYUxFRDZTRE9J?oc=5" target="_blank">New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy
The Manila Timesgeneral

CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

<a href="https://news.google.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?oc=5" target="_blank">CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
Dr Costa on Teclistamab Plus Daratumumab vs Daratumumab-Based Triplets in Relapsed or Refractory Multiple Myeloma
OncLivegeneral

Dr Costa on Teclistamab Plus Daratumumab vs Daratumumab-Based Triplets in Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOVFc4SjlKSEQ4R3hXT2hVWEhuYjZtSnZNNmQxT1l4a2ZVMmljT08zbEY5UnYtY2dzV283YnJTZE5jQm54WFFDUF9Mc2ZzUVpudjF0TlBZTWhSYWFuLTlUcTJ1TkJLdmNpOUliX01lR0p4blVsNnlaXzMzZlZDM1F1djgwYjkzcS1sMGdrOHJzZjR0YzBXQkp6U3NodmlZcWpJMWhfLWcxbE80X01LMlltdjZTaFFsQUtwaDdGVHhaNkpLM1NfUzdfZFB2NGJFOGl5T0oyMUk3UGxsQQ?oc=5" target="_blank">Dr Costa on Teclistamab Plus Daratumumab vs Daratumumab-Based Triplets in Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Al-Ola Abdallah Reviews Long-Term Teclistamab Outcomes in Multiple Myeloma
Oncodailygeneral

Al-Ola Abdallah Reviews Long-Term Teclistamab Outcomes in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBSTVFyMk42SFVZYmtXQWpPR2NwVVdweDZfdWJGaFRHNVozNVdVdE9vcUNyTWNZd1Job2NyeW1pck9NcU96RjRUUWxNSjFCelZtaUgzRTFBSllrRzU2eUtjMHdn?oc=5" target="_blank">Al-Ola Abdallah Reviews Long-Term Teclistamab Outcomes in Multiple Myeloma</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
NEJMgeneral

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9seUZqR0NLWUNYSi1tU2NDdERiM1BIX0NsNXNoQVh6a0VGUzM3d1NTVlVHZ3dBU1l3clp4N2FNbnE5clFjTGctZll2dDJQMS11NmY5TmtvaU9UNEhCdFBB?oc=5" target="_blank">Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
PharmaTimesgeneral

Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOZDdWZmplRHV0T2ota1VCbXdvaHRPYmZxMEJpamhneC13cTEzbktoOVBlQWh2NnhpYUZOTjVsSF9hSzE3eWcxY29kWFN1d09nb01NaTR4ZXdBVzBuN2ZWV1dqbTRGMkpnWUVJVFZTa3ZDcWVZY0xfLTBtNUN4U204cWpMVHZzLWNNMWdHLTVMbDNabm9jZEtxX0pTZ214ZEF4VVpIOGU5MA?oc=5" target="_blank">Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination</a>  <font color="#6f6f6f">PharmaTimes</font>

Read Full StoryMore like this
Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal
Naturegeneral

Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MTDR1TjRkM3JyUDdGd1FnOHRHcXFOU1Y5R2YxVHRXQndyVDIzdm9XZjZCUklvaGduTGRyVzlRN1dHS1h2Y0lYM1FWanlGam5fUDVkR25Ua3RwMy1nT0pv?oc=5" target="_blank">Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Parag Roy: Teclistamab + Daratumumab Sets New Standard in Early Relapsed Myeloma
Oncodailygeneral

Parag Roy: Teclistamab + Daratumumab Sets New Standard in Early Relapsed Myeloma

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFBrcnJaajFvbm40Qnh1bC1fU0lVejB2d3R4NUVYclpxWDQ1TGZsR3p4anZ2T3BiNEZ2R2lIZGN1WllsZGZ3RFVRdy1VbVdxcG14emVqYVNsbzU?oc=5" target="_blank">Parag Roy: Teclistamab + Daratumumab Sets New Standard in Early Relapsed Myeloma</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma
HMP Global Learning Networkgeneral

MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPY01pc2xXTDZkdXY1ZjhsNllyYmdtQzFMWWdDSGdjcVhpdkdOYVN0aGJiQU5BVlRGTEQyRTFibnF3LTJ2cWh3bG5tTXJRb3FiTm12ekJxYmFPS1ZmMVFfUjJ2YmVFSTlaSHpDSThwYmZQWTljRXJub3RHVGpnRDlwX0tKQTZRYmU2MWp6a1VHWlk0RTJobWd4Yi13TXpmc1M4eTIyMkxITm4tY19SSV9iV3VaTGN2T0RDQTVaaC1wSDZvdmhfVjdVV0dsMkk0UQ?oc=5" target="_blank">MajesTEC-9 Establishes Teclistamab as a New Standard in Early Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">HMP Global Learning Network</font>

Read Full StoryMore like this
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
The Manila Timesworld

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care

<a href="https://news.google.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?oc=5" target="_blank">European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026
OncLivegeneral

Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYXNVWWRXWFZ0RmYwOVNRdUd6dUxIMlVHOXVkXzBSWTJyc3NJaWJsTm9teGFpLWxDeDZDUkxUQ0Z5aWdrakpPN2dLMFY2cnNBandHLW1TWVdHWjlGa0ZHc3NUWEpGVDFURUl2SHNLeHN6eTd0Y0ROWTBuUjhENGsxaFFCOFF2TTF2VUh6cEZmTkhucXR5cG1uZjhuMElkbl9TeXhzYUhOdUVVSEhqV2c0Mm5HUmg1Q194MHJR?oc=5" target="_blank">Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Teclistamab in Relapsed or Refractory Multiple Myeloma
NEJMgeneral

Teclistamab in Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1BbGdBeEZkZkhMWkJpYklXd2t3MWVYYnJTb2o2NWlpd1dTLTdwc2phdVBVNFgwbDVOckNCa3NRSDdTbjROZXNJVzNERkljZmhUYkFncGk4NjVwMTVuLU1iUQ?oc=5" target="_blank">Teclistamab in Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Oncodailygeneral

MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBuZ0V2clhjNm9wMlZhSmNiN3BHNzE4a1VteklrcVNTQmdObTRxZ1hfeWJDaUtMQWtyY2lkWkY1N01Nb1hKZlIwMzVzYlJ0cXRTR3gyT0lHSQ?oc=5" target="_blank">MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Natureworld

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1WS20wNDB2RGRrLU52cmtHMDAxclZtZzJyZE1aS2hSLUhidHVvdFlTbVNZZGIzN3JoTWtCNVQyeHhJVUlid1hma0p1cVA4UHlEcElBY2Y0M1M3S1dZM2t3?oc=5" target="_blank">Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study | Blood Cancer Journal
Natureworld

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0tSE5xcjlEYXJUR2JYRFpBZmFxN1l5VHFGNTkwTXlLRnhzSGZILWkzbWw0Uk1YY0lOYzFUNGZFcXZKWEdoZ0JKZlk2UDJ0T2c4dXZSYVZmTWF6cHIwUGZJ?oc=5" target="_blank">Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study | Blood Cancer Journal
Naturegeneral

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LeURRY1U5WXVMSmlndkxXOF9oeFRUS3lWOTJLNlp5aXJTSXZRY3V1RXc0UlZxUG0zd0s3LXNFNEdaMEFXU3pyZjA2RERVSFhsd09IUnBMWDB4RVRzbENB?oc=5" target="_blank">Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal
Natureworld

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9SWWRxN0NIV3A5Q19nTGVKQWJoUlM5dXJhVDNDSmRadmV5b2ZLTnJoSjJuVmZKR0hoVEVUdXpiLWNrUzR5bXBVb2xEN0tfQ1lURnVFeGMtR0xBaVVKc2Qw?oc=5" target="_blank">Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal
Naturegeneral

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5oc3BmaHg5ZnpreEltV0NKeS1Rb094dGFlNDBDdHNRYi0xLXF1ZmVKcjh5dXZvblY3ZDIxQWVacTZIUnphVTZzR1l1SW1tNXJ4WGVPOVVZR0ZhdTFOdXZr?oc=5" target="_blank">Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal
Natureworld

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE41ZkRRWkVQV2EtbjNhbWs4SzNsRXd5VE1ycG5qT1I0akpldV8wejJXdm0zb2gxTG5EUF9zSFVWYjFpT0FVOG5FcVlBNDEzQjg4UDVPMVFTakxtaUM1SWdz?oc=5" target="_blank">Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma
The ASCO Postgeneral

Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOQUVuSjlaQS0taWhjRzdzQ0RiTFJuLUZHTkZGY25wdTFscVZ1el9XVjRfRVdENDA3bEx1Qzh1bEpOeDBVT296OHh3R1lsdjU3eU1TdS0xSTl0aHgwLUFKNDFscHNkVmk3V2J2T2N0NW9FUGNWb3EtR0lyVGcydWdBMzV6dERuMW9NSGo2NGh3WWZqVVg0RERvbURvWUJIR0Z4WkZfYmxpOG44dWI0X29IQmtxYXpGYnlMODUzYVBFSE90LUNWcTlsRHZhdw?oc=5" target="_blank">Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Natureworld

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5zcG5uYV9KM1NNQ0JQUnVoZmdFT01xWC1nVXRjUGVlc0pEMDBzZFBzZVNkYlpKWTh3NEg1ZUcyWXRwcXdWR01IT1JqOG9MeElLSW9QWkU5QWoyUGFMR2xr?oc=5" target="_blank">Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world analysis of teclistamab in 123 RRMM patients from Germany - Leukemia
Natureworld

Real-world analysis of teclistamab in 123 RRMM patients from Germany - Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBzQXNKeEtpempINDloRVpLeXVpbk54OUU5UzlJT1dmZDF6LXI4RmhGcy1UUVBEUThEVmhUMWpXdVNtYUpXN3dEMDViTVd4dXNOZE05WVJ0M0ZCY1NVazZz?oc=5" target="_blank">Real-world analysis of teclistamab in 123 RRMM patients from Germany - Leukemia</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
Naturegeneral

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE83R2h2a1dGcU95WVNGV2dJQmFiTVNVOE5TMlFrT2FXYi1XV25iTTdOanpFS3JET1gzVlhablNtODhlUHRXVUg2QlNhRnJCUzZLc0xKaUxYcmpBdTljMjc4?oc=5" target="_blank">Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal
Natureworld

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA3MzNqeV80enZnNDY5QXczckY5SEJoOWZwYXdLbUNraGtXQ3Bscy1tbVFYMUg2Z05xYkljNWt6MkpfaUxPcmRRbHdPVzVja2lHRVY3cDNabG5vRUwzVFdZ?oc=5" target="_blank">The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab | Blood Cancer Journal
Natureworld

Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5iRDZibGZzUm9pd3FnRnh5OFlBclZqeGR5Y04wczhxVFUycGtJbk9jbUxkMkNFM1V1aU5Hai1JU0tadDFNT0gxdUk0ZDB4cENVX1ZIbjJVMFJSX19ILVNz?oc=5" target="_blank">Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Earlier Use of Bispecific Antibodies in Multiple Myeloma: Current Data and Remaining Questions
ASCO Daily Newstech

Earlier Use of Bispecific Antibodies in Multiple Myeloma: Current Data and Remaining Questions

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPT2ZXYU9LYjF5M0R5OHJIUVZsUUwxYVJJdjRKMzRQR29hMmIxYWtnVmdLTkJQTmt3a2FKbG9ZTU1DbUg0S0o0TTR3eEp4NGJoUUg3ZzdNQ2JjbnJzcDBibWxLUzNZMENsY0w5b0xuZmFvS3ZaN0xkWTZ6S3l6UWFNczZlM0wwUHVONG1yYk44UF9Nazg1dkFkMzZGcUpzTmVfM21jQkwzajdNX1J4b1NTdTg3UUU4c044T0JZbGV3?oc=5" target="_blank">Earlier Use of Bispecific Antibodies in Multiple Myeloma: Current Data and Remaining Questions</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
Naturegeneral

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LQ0VmLVpfeGxYQnY5LTdBZnJVM2xvdXhYNFJ1c1hFaVg0Q19rc3Q0Q00zeU9BT0RNY2p2X19HZUtvb0tCMHdnOExSVE56MDlGUGJ1WWhNejk1SHZwLS1v?oc=5" target="_blank">Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
The Lancetgeneral

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQLXUyWXQ2WGg5LXRhLU4tQjYwMjJUYnlpU256UlpqUU9RTHBWY2xDc3hTWnZsbDJ6UV9TUTdVZ0FqZXIzMktOVElWcHA5MzBiMlNxX1VZemx0bGZfaW9jNHFrUU1mOVZVbmJFNHRCUDB0VmNvUGhqTkQ0Y3JySS0yeWZxNG9rcEhhdC1F?oc=5" target="_blank">Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
"Teclistamab in Relapsed o" — Live Google News Trends & Headlines